3.01
Abcellera Biologics Inc stock is traded at $3.01, with a volume of 1.22M.
It is down -0.67% in the last 24 hours and down -28.78% over the past month.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
See More
Previous Close:
$3.04
Open:
$3.02
24h Volume:
1.22M
Relative Volume:
0.30
Market Cap:
$902.50M
Revenue:
$38.03M
Net Income/Loss:
$-146.40M
P/E Ratio:
-5.7885
EPS:
-0.52
Net Cash Flow:
$-121.38M
1W Performance:
-2.59%
1M Performance:
-28.78%
6M Performance:
-31.21%
1Y Performance:
-0.34%
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ABCL
Abcellera Biologics Inc
|
3.015 | 909.98M | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.80 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.38 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
829.66 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.60 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.48 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-07-25 | Resumed | Leerink Partners | Outperform |
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
AbCellera Biologics Inc (ABCL) Misses Q4 2025 Earnings Estimates — EPS $-0.19 vs $-0.16 Expected - AlphaStreet News
AbCellera Biologics Faces Stock Volatility Amid Strategic Decisions - timothysykes.com
AbCellera Biologics Inc (ABCL) down 23% since Q3 2025 results - MSN
Is AbCellera Biologics Inc affected by consumer sentimentJuly 2025 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
AbCellera Biologics (ABCL) Projected to Post Earnings on Tuesday - MarketBeat
Aug Mood: Is AbCellera Biologics Inc a potential multi baggerJuly 2025 Rallies & Expert-Curated Trade Recommendations - baoquankhu1.vn
AbCellera Biologics (NASDAQ:ABCL) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Trading Up 8.3%Still a Buy? - MarketBeat
AbCellera Biologics Inc. (ABCL) Stock Analysis: A Biotech With A 234% Potential Upside - DirectorsTalk Interviews
How resilient is AbCellera Biologics Inc. stock in market downturnsJuly 2025 Weekly Recap & Daily Entry Point Alerts - mfd.ru
State of Michigan Retirement System Acquires 350,775 Shares of AbCellera Biologics Inc. $ABCL - MarketBeat
Is AbCellera’s Biotech Platform Setting New Standards for Pharmaceutical Innovation - Kalkine Media
Painful Week for Individual Investors Invested in AbCellera Biologics Inc. (NASDAQ:ABCL) After 10% Drop, Institutions Also Suffered Losses - 富途牛牛
Travel Stocks: Is Lifeway Foods Inc forming a double bottom2025 Analyst Calls & Daily Chart Pattern Signals - baoquankhu1.vn
AbCellera to Present at Upcoming Investor Conferences in March and April 2026 - Investing News Network
How AbCellera Biologics Inc. stock trades before earnings2025 Earnings Surprises & Stock Timing and Entry Methods - mfd.ru
Is AbCellera (ABCL) Trading Its Platform Identity For Higher-Stakes Clinical Ambitions? - Sahm
Short sales on the TSX: What bearish investors are betting against - The Globe and Mail
Will AbCellera Biologics Inc. stock maintain growth story2025 Pullback Review & Long-Term Growth Stock Strategies - mfd.ru
OpenAI considers backing AI-led drug discovery firms: report - Seeking Alpha
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - Insider Monkey
What does Wall Street think about AbCellera Biologics Inc. (ABCL)? - MSN
AbCellera’s ABCL635 Phase 2 Start Highlights Menopause Focus And Valuation Gap - Yahoo Finance
AbCellera Biologics (ABCL) Valuation Check After Mixed Long Term Shareholder Returns - Yahoo Finance
AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets - Sahm
Reassessing AbCellera Biologics (ABCL) After A Sharp 16.8% Weekly Share Price Drop - Yahoo Finance
What Does Wall Street Think About AbCellera Biologics Inc. (ABCL)? - Insider Monkey
Exit Recap: Why is AbCellera Biologics Inc stock going downJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Can AbCellera Biologics Inc disrupt its industry2025 Winners & Losers & Free High Return Stock Watch Alerts - baoquankhu1.vn
Strategic Moves Shape ABCL’s Market Position - StocksToTrade
AbCellera’s Market Moves: Key Developments - timothysykes.com
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Rating of "Hold" by Brokerages - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Trading Down 6.1%Here's Why - MarketBeat
Is AbCellera Biologics Inc a top pick in the sectorPortfolio Value Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
AbCellera Biologics Inc. (ABCL) Stock Analysis: Exploring a Promising 111.93% Potential Upside - DirectorsTalk Interviews
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 - PharmiWeb.com
AbCellera Biologics (NASDAQ:ABCL) Trading Up 11.6%Here's Why - MarketBeat
A Look At AbCellera Biologics (ABCL) Valuation After ABCL635 Advances Into Phase 2 Trial - Sahm
AbCellera Biologics (NASDAQ:ABCL) Stock Rating Lowered by Wall Street Zen - MarketBeat
Why AbCellera Biologics Inc. stock could rally in 2025High Dividend Yield Stocks & Invest Like A Pro - bollywoodhelpline.com
Is AbCellera (ABCL) Quietly Recasting Its Platform As A Menopause-Focused Drug Developer? - simplywall.st
Aug Reactions: What is the implied volatility of Sonida Senior Living IncMarket Movers & Weekly Hot Stock Watchlists - baoquankhu1.vn
Citizens Financial Group Inc. RI Acquires Shares of 261,890 AbCellera Biologics Inc. $ABCL - MarketBeat
AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 - Yahoo Finance
AbCellera Biologics Inc Doses First Patients in Phase 2 Trial for ABCL635 - TradingView — Track All Markets
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - Investing News Network
AbCellera Biologics (NASDAQ:ABCL) Shares Down 5.6%Should You Sell? - MarketBeat
AbCellera begins phase 2 trial of non-hormonal menopause treatment By Investing.com - Investing.com Nigeria
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause - BioSpace
AbCellera begins phase 2 trial of non-hormonal menopause treatment - Investing.com
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):